NEW YORK, NY / ACCESSWIRE / January 25, 2017 / The Biotech Industry had a solid start to the year before comments made by President Trump triggered a major selloff within the industry. The iShares NASDAQ Biotechnology Index ETF gained approximately 8.0 percent from the start of the year through Jan. 10th, but has since fallen approximately 5.5 percent. For the week ending Jan. 18th, stocks from the biotech sector experienced $526 million in net outflows, compared to $726 million in inflows in the week prior, according to Raymond James.

Register with us now for your free membership and gain access to our latest research reports at: RDInvesting.com

"We have to get our drug industry coming back. Our drug industry has been disastrous, they're leaving left and right. They supply our drugs but they don't make them here, to a large extent," President Trump said at a news conference on January 11th. "And the other thing we have to do is create new bidding procedures for the drug industry, because they're getting away with murder," the President said.

Nektar Therapeutics (NASDAQ: NKTR)

Get Your Up-To-Date Nektar Therapeutics Research Report Click Here

Nektar Therapeutics' shares gained 1.00 percent to close at $12.14 a share Monday. The stock traded between $11.75 and $12.18 on volume of 967,112 shares traded. Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, Baxalta's ADYNOVATE, UCB's Cimzia for Crohn's disease and rheumatoid arthritis, and Amgen's Neulasta for neutropenia. Nektar Therapeutics' President and Chief Executive Officer, Howard W. Robin, recently presented at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2017.

Acasti Pharma Inc. (NASDAQ: ACST)

Get Your Up-To-Date Acasti Pharma Research Report Click Here

Acasti Pharma's shares jumped 16.94 percent to close at $1.45 a share Monday. The stock traded between $1.37 and $1.75 on volume of 1.65 million shares traded. Acasti's lead drug candidate, CaPre, has completed two Phase 1 bioavailability and pharmacokinetic trials in healthy volunteers, and two Phase 2 clinical trials in patients with hypertriglyceridemia. The company reported a net loss of $2.4 million, or $0.22 loss per share, for the third quarter of fiscal 2017, compared to a net loss of $2.2 million, or $0.21 loss per share, in the third quarter of fiscal 2016. The company had $5.8 million in cash and short term investments as on Nov 30, 2016 and the management is looking to raise additional funds to maintain company?s financial health.

"A highlight of Acasti's third quarter was the reporting of positive data from our Phase 2 Bridging Study for CaPre, which gives us confidence that we'll proceed with the U.S. Food and Drug Administration's (FDA) more expedited 505(b)(2) pathway, pending the outcome of our end of Phase 2 meeting with the agency," said Jan D'Alvise, president and CEO of Acasti Pharma, in their fiscal third quarter earnings release.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com